ORGANIZATION - Pharma Japan -

Friday, October.19.2018

Remember Me

Home＞ORGANIZATION

Regulatory Science Society Says “No” to Off-Label Info Supply by Drug Reps Conditionally OK’ed in Draft MHLW GLs
August 24.2018
Drug Wholesalers Post Virtually Flat Sales in FY2017: JPWA
August 10.2018
Total No. of Sales Reps Shrinks for 4 Years in a Row at 62,433: Survey
July 27.2018
Generic Use Rate at 74.1% in January-March: JGA
July 4.2018
Yokokura Wins 4th Term to Lead Japan Medical Association
June 25.2018
Expand Exemption Criteria in New Off-Patent Price Cut Rule: Japan Pharma Lobby
June 19.2018
Japan Pharma Group Calls for Careful Approach on PMP Deduction for Comparator Drugs
June 19.2018
Don’t Make Coverage Decision on CEA, Tweak Prices with Limited Scope: FPMAJ
June 18.2018
Scrap Unfair Company Criteria for Price Maintenance Premium: Japan Trade Group
June 18.2018
FPMAJ Welcomes Chuikyo’s Openness to Views of Experts on CEA: Drug Pricing Committee Chair
June 18.2018

＜ Prev 1 2 3 4 5 6 7 8 9 10 Next ＞

There’s Room for Growth in Biosimilar Space, but Who Will Grab It?

G1/G2 Rule：
G1/G2ルール

Finding Captains in Your Organization

Prescribers Asked to Stop New Enbrel Biosimilar Use as Maker Can’t Keep Up with Demand(Oct.19)

Council Approves MHLW’s Plan to Deal with Difficult-to-Develop Drugs and Indications(Oct.19)

PMDA to Focus on Proper Use of Sakigake and Conditional Approval Systems in Its 4th Midterm Plan(Oct.19)

Takeda Earns Japan Clearance for Shire Acquisition(Oct.19)

Council OKs Public Knowledge-Based Applications for Add’l Pediatric Indications for Blopress(Oct.19)

1.: MHLW Panelists Frown on Use of Economic ...
2.: Hep C Market Shrinking towards Disease E...
3.: Chugai Sues Daiichi Sankyo, Pfizer over ...
4.: Nobel Laurate Honjo Prods Minister on In...
5.: Shonan iPark to Focus on Disease Prevent...